Business Trends– category –
-
ARO-DIMER-PA: Arrowhead’s Phase 1/2a siRNA knockdown specs
Cyagen Lab Notes USA Overview Arrowhead Pharmaceuticals announced promising interim Phase 1/2a clinical data for ARO-DIMER-PA, a novel dual-function RNAi therapeutic targeting cardiometabolic diseases. This single siRNA molecule simultan... -
Enicepatide: Roche’s Phase II results for diabetes and obesity
Roche Switzerland Overview On September 22, 2026, Roche announced positive topline Phase II results for its once-weekly dual GLP-1/GIP receptor agonist, enicepatide (CT-388), in adults with type 2 diabetes and overweight or obesity. The ... -
SORT LNPs explained: Novel 5th lipid component for organ delivery
Patsnap Singapore Overview Patsnap's September 18, 2026 analysis highlights Selective Organ Targeting (SORT) Lipid Nanoparticles (LNPs) as a groundbreaking technology for highly efficient, organ-specific delivery of nucleic acid payloads... -
Elunetirom: Phase 2 AMPLIFY-BD trial results for bipolar depression
Pharmacally International Overview Elunetirom demonstrated favorable results in the Phase 2 AMPLIFY-BD open-label trial for bipolar depression, significantly reducing depressive symptoms and improving patient function. In 21 adults with ... -
LUNAR 2.0: Arcturus Therapeutics mRNA expression roadmap
Morningstar USA Overview Arcturus Therapeutics announced interim Phase 2 results for ARCT-810 in OTC Deficiency and unveiled its next-generation mRNA delivery platform, LUNAR 2.0™. ARCT-810 demonstrated a favorable safety profile and pro... -
mRNA Vaccine LNP: South Korea’s 2026 organ targeting specs
Vertex AI Search South Korea Overview In South Korea, new lipid nanoparticle (LNP) strategies for mRNA vaccines are being developed, including Selective Organ Targeting (SORT) to lung, spleen, and lymph nodes, and ligand conjugation to L... -
Korsana Biosciences Secures $380 Million in PIPE Financing to Advance Alzheimer’s Disease Pipeline
Panabee (Korsana Biosciences) United States Overview On September 10, 2026, Korsana Biosciences successfully completed a $380 million PIPE (Private Investment in Public Equity) financing to accelerate its Alzheimer's disease (AD) therape... -
Samsung Biologics Secures $262M Manufacturing Contract with European Pharma Amid Peptide Expansion and CDMO Capacity Growth
BioProcess International South Korea Overview On September 10, 2026, Samsung Biologics announced a $262 million manufacturing agreement with an undisclosed European pharmaceutical company. This substantial contract will further accelerat... -
Evonik Breaks Ground on Biotechnology Expansion in Slovakia, Strengthening European Pharmaceutical Manufacturing Hub
Evonik Germany Overview On September 14, 2026, Evonik initiated construction for a significant biotechnology manufacturing expansion at its Fermín site in Slovakia. This investment aims to bolster the company's production capacity for ac... -
Rani Therapeutics Achieves 84% Bioavailability for Oral Ustekinumab Biosimilar; Oral GLP-1s Drive Commercial Success in Biopharma Delivery
Drug Delivery Leader USA Overview The successful FDA approval and commercial launch of oral semaglutide (Wegovy) and orforglipron highlight the critical role of oral delivery in chronic disease management, significantly improving patient...
